A phase II study of TSU-68 in patient with metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2610479
下载链接
链接失效反馈官方服务：
资源简介：
Intervention name : TSU-68, S-1, Oxaliplatin
INN of the intervention : TSU-68:orantinib, S-1: tegafur, gimeracil, oteracil potassium, oxaliplatin
Dosage And administration of the intervention : Treatment is repeated every 21 days as follows: S-1 is orally administered at 35 mg/m2 twice a day after meals on day 1-14 followed by 7 days rest. Oxaliplatin is given as an intravenous infusion of 130 mg/m2 on day 1. Additionally for the patients of group A, TSU-68 is orally administered at 200 mg twice a day after meals on day 1 to 21.
Control intervention name : S-1, Oxaliplatin
INN of the control intervention : S-1: tegafur, gimeracil, oteracil potassium oxaliplatin
Dosage And administration of the control intervention : Treatment is repeated every 21 days as follows: S-1 is orally administered at 35 mg/m2 twice a day after meals on day 1-14 followed by 7 days rest. Oxaliplatin is given as an intravenous infusion of 130 mg/m2 on day 1.
Primary outcome(s): Progression free survival
RECIST (ver. 1.1)
Study Design: Open-label, multicenter, randomized phase II study
创建时间：
2010-03-15
